Clavis Pharma ASA is a clinical stage oncology focused pharmaceutical company based in Oslo, Norway, with a portfolio of novel
anti-cancer drugs in development. These potential breakthrough products are New Chemical Entities (NCEs) made using Clavis
Pharma's Lipid Vector Technology (LVT) chemistry to introduce new properties to already established, commercially successful drugs.
Clavis Pharma intends to commercialise its products through strategic alliances and partnerships with experienced oncology
businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities.
Data generated suggests the resulting patentable NCEs offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration, altered metabolism and, in certain cases, additional modes of action.
Clavis Pharma's has several drug candidates in formal development studies:
- Elacytarabine, an optimised form of cytarabine, a leukaemia drug - currently in Phase III, a randomized, controlled registration study in late-stage acute myeloid leukaemia
- CP-4126, an improved version of gemcitabine - currently in a Phase II comparative study with gemcitabine for the treatment of pancreatic cancer
- CP-4200, an azacitidine derivative - in preclinical development for myelodysplastic syndrome (MDS), often a precursor to leukaemia.
CP-4126 is partnered with Clovis Oncology, Inc.
The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange (ticker: CLAVIS).